Alimera Sciences, Inc. (ALIM) News

Alimera Sciences, Inc. (ALIM): $5.08

-0.17 (-3.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ALIM News Items

ALIM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALIM News Highlights

  • For ALIM, its 30 day story count is now at 5.
  • Over the past 23 days, the trend for ALIM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ALIM are HUM and MG.

Latest ALIM News From Around the Web

Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.

Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network

ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathyATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it has entered into an agreement with the Jaeb Center for Health Research

Yahoo | September 23, 2022

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland

Reimbursement granted with no restrictions to the labelATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN ® (fluocinolone acetonide intravitreal implant)

Yahoo | September 20, 2022

Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?

Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Yahoo | September 19, 2022

Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?

Here is how Humana (HUM) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.

Yahoo | September 2, 2022

Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

Positive findings from the RIVER study and data on retreatment with ILUVIEN availableATLANTA, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in more than 20 scientific abstracts d

Yahoo | August 31, 2022

Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors

Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Yahoo | August 29, 2022

Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why

Alimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Yahoo | August 19, 2022

Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?

Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year.

Yahoo | August 17, 2022

Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will deliver a corporate presentation at the HC Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17, 2022. The

Yahoo | August 10, 2022

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Reimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN® (fluocinolon

Yahoo | August 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5723 seconds.